Literature DB >> 10563434

Neurologic sequelae of treatment of primary CNS lymphomas.

U Schlegel1, H Pels, R Oehring, I Blümcke.   

Abstract

Novel efficient and aggressive treatment protocols for primary CNS lymphomas have resulted in an increasing number of long term survivors. Follow up data show that in a substantial fraction of these patients, treatment benefits are overshadowed by neurotoxic sequelae. Neurotoxicity especially affects the older age group, presenting as cognitive dysfunction, ataxia or dementia as a consequence of leukoencephalopathy and brain atrophy. The combination of radiotherapy and chemotherapy seems to be particularly hazardous, though data are too sparse to draw any definite conclusions yet. Long term follow up of patients included in clinical studies therefore should not only evaluate survival or time to tumour progression, but also serial neuropsychometric evaluation and quality of life assessment.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10563434     DOI: 10.1023/a:1006214804736

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  45 in total

Review 1.  Primary cerebral malignant non-Hodgkin's lymphomas: a retrospective clinical study.

Authors:  D F Braus; K Schwechheimer; H K Müller-Hermelink; G Schwarzkopf; B Volk; F Mundinger
Journal:  J Neurol       Date:  1992-03       Impact factor: 4.849

2.  Prognostic factors in the diagnosis and treatment of primary central nervous system lymphoma.

Authors:  I F Pollack; L D Lunsford; J C Flickinger; H L Dameshek
Journal:  Cancer       Date:  1989-03-01       Impact factor: 6.860

3.  Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome.

Authors:  J Glass; M L Gruber; L Cher; F H Hochberg
Journal:  J Neurosurg       Date:  1994-08       Impact factor: 5.115

4.  Osteogenic sarcoma: MR signal abnormalities of the brain in asymptomatic patients treated with high-dose methotrexate.

Authors:  H H Lien; V Blomlie; G Saeter; O Solheim; S D Fosså
Journal:  Radiology       Date:  1991-05       Impact factor: 11.105

Review 5.  Neurological complications of antineoplastic therapy.

Authors:  W R Shapiro; D F Young
Journal:  Acta Neurol Scand Suppl       Date:  1984

6.  Combined modality therapy for primary CNS lymphoma.

Authors:  L M DeAngelis; J Yahalom; H T Thaler; U Kher
Journal:  J Clin Oncol       Date:  1992-04       Impact factor: 44.544

7.  Good performance status of long-term disease-free survivors of intracranial gliomas.

Authors:  L Kleinberg; K Wallner; M G Malkin
Journal:  Int J Radiat Oncol Biol Phys       Date:  1993-04-30       Impact factor: 7.038

8.  Primary central nervous system lymphoma: a role for adjuvant chemotherapy.

Authors:  M C Chamberlain; V A Levin
Journal:  J Neurooncol       Date:  1992-11       Impact factor: 4.130

9.  Progressive ascending paralysis following administration of intrathecal and intravenous cytosine arabinoside. A Pediatric Oncology Group study.

Authors:  S F Dunton; R Nitschke; W E Spruce; J Bodensteiner; H F Krous
Journal:  Cancer       Date:  1986-03-15       Impact factor: 6.860

10.  Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of radiation therapy oncology group protocol 88-06.

Authors:  C Schultz; C Scott; W Sherman; B Donahue; J Fields; K Murray; B Fisher; R Abrams; J Meis-Kindblom
Journal:  J Clin Oncol       Date:  1996-02       Impact factor: 44.544

View more
  9 in total

Review 1.  Can neural stem cells be used to track down and destroy migratory brain tumor cells while also providing a means of repairing tumor-associated damage?

Authors:  M Noble
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-07       Impact factor: 11.205

Review 2.  Radiation dose-volume effects in the brain.

Authors:  Yaacov Richard Lawrence; X Allen Li; Issam el Naqa; Carol A Hahn; Lawrence B Marks; Thomas E Merchant; Adam P Dicker
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-01       Impact factor: 7.038

Review 3.  [Acute central nervous symptoms in oncologic patients].

Authors:  K Orlopp; I G H Schmidt-Wolf; H Urbach; U Schlegel
Journal:  Internist (Berl)       Date:  2005-01       Impact factor: 0.743

Review 4.  [White matter alterations after chemotherapy and radiation].

Authors:  A Simgen
Journal:  Radiologe       Date:  2018-12       Impact factor: 0.635

5.  Computer-based assessment of cognitive functions in brain tumor patients.

Authors:  Klaus Fliessbach; Sabine Rogowski; Christian Hoppe; Michael Sabel; Mathias Goeppert; Christoph Helmstaedter; Pasquale Calabrese; Gabriele Schackert; Joerg-Christian Tonn; Matthias Simon; Uwe Schlegel
Journal:  J Neurooncol       Date:  2010-05-07       Impact factor: 4.130

6.  Primary Central Nervous System Lymphoma.

Authors:  Denise M. Damek
Journal:  Curr Treat Options Neurol       Date:  2003-05       Impact factor: 3.598

7.  Long-term remission of primary central nervous system lymphoma by intensified methotrexate chemotherapy.

Authors:  Takao Watanabe; Yoichi Katayama; Atsuo Yoshino; Chiaki Komine; Takakazu Yokoyama; Takao Fukushima
Journal:  J Neurooncol       Date:  2003-05       Impact factor: 4.130

Review 8.  Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphoma.

Authors:  M Ponzoni; S Issa; T T Batchelor; J L Rubenstein
Journal:  Ann Oncol       Date:  2013-11-20       Impact factor: 32.976

9.  Complete and Durable Responses in Primary Central Nervous System Posttransplant Lymphoproliferative Disorder with Zidovudine, Ganciclovir, Rituximab, and Dexamethasone.

Authors:  James P Dugan; Bradley M Haverkos; Lynda Villagomez; Ludmila K Martin; Mark Lustberg; John Patton; Marisa Martin; Ying Huang; Gerard Nuovo; Fengting Yan; Robert Cavaliere; Joyce Fingeroth; Shannon C Kenney; Richard F Ambinder; Gerard Lozanski; Pierluigi Porcu; Michael A Caligiuri; Robert A Baiocchi
Journal:  Clin Cancer Res       Date:  2018-04-09       Impact factor: 12.531

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.